Ozmosi | Serrapeptase Drug Profile

Product Description

Mechanisms of Action:

Novel Mechanism: No

Modality: Peptide/Protein

Route of Administration: Oral

FDA Designation: *

Approval Status: Not Approved

Approved Indications: None

Known Adverse Events: None

Company: Hayat
Company Location:
Company CEO:
Additional Commercial Interests: None

Clinical Description

Countries in Clinic:

Active Clinical Trial Count:

Recent & Upcoming Milestones

Highest Development Phases

Phase 4: Inflammation|Trismus

Phase 3: Trismus

Trial ID	Trial	Phase	Trial Status	Disease	Primary Completion Date	Probability of Success	Latest Trial Update Date	Data Updated
NCT07304882	CESE-3M	P3	Completed	Trismus	2025-01-04		2025-12-27	Primary Endpoints\|Treatments
NCT02493179	Ser.01	P4	Unknown status	Trismus\|Inflammation	2016-01-01		2019-03-20

Recent News Events

Date	Type	Title
06/25/2024	News Article	Nutraceuticals Market size is set to grow by USD 279.8 billion from 2024-2028, Increasing cost of medical treatment to boost the market growth, Technavio
05/20/2024	PubMed	Purification, functional characterization and enhanced production of serratiopeptidase from Serratia marcescens MES-4: An endophyte isolated from Morus rubra.
05/20/2024	News Article	BioMed Nutrition Unveils Groundbreaking NeuroGen® for Optimal Nerve Health and Enhanced Well-being
05/01/2024	PubMed	Does serratiopeptidase prevent thoracic surgery in patients of hydropneumothorax of tubercular aetiology?
05/01/2024	PubMed	Calcium-induced structural transitions are central to the folding, function, and processing of serratiopeptidase zymogen into mature form.
09/27/2023	News Article	Enteric-coated Tablets Market Outlook for Forecast Period (2023 to 2030)
09/27/2023	News Article	Enteric-coated Tablets Market Development Trends and Business Opportunities till 2029

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you've used PRYZM, we hope you're able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions

Session Expiring Soon

Serrapeptase

Alternative Names: serrapeptase, serratiopeptidase Clinical Status: Inactive Latest Update: 2025-12-26 Latest Update Note: Clinical Trial Update